Oncocyte to Report Second Quarter 2021 Financial Results on Tuesday, August 10
July 27, 2021 10:35 ET
|
Oncocyte Corporation
IRVINE, Calif., July 27, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear...
Oncocyte Celebrates Women Thoracic Surgeons in #ShesMySurgeon Campaign
June 22, 2021 08:00 ET
|
Oncocyte Corporation
IRVINE, Calif., June 22, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics and monitoring company with the mission to improve patient outcomes by providing clear...
Oncocyte Announces Collaboration with Gruppo Oncologico del Nord Ovest to Evaluate Oncocyte’s DetermaIO Test in Colorectal Cancer, the Second Leading Cause of Cancer Mortality Globally
June 03, 2021 08:00 ET
|
Oncocyte Corporation
Gruppo Oncologico del Nord Ovest, a Leading European Clinical Trials Group, Conducts Independent Investigator-Sponsored Clinical Trials for Pharmaceutical Targeted and Immune Therapies If...
Oncocyte Selected as New “Day One” Launch Site for QIAGEN’s Companion Diagnostics Test to Identify Patients for Amgen’s Newly FDA-Approved Drug LUMAKRAS (Sotorasib) For Advanced Stage Lung Cancer
June 01, 2021 08:00 ET
|
Oncocyte Corporation
Oncocyte’s Nashville CLIA lab now offers the Therascreen RGQ KRAS test Addition of the Therascreen RGQ KRAS test strengthens Oncocyte’s one-stop shop offering for lung cancer treatment decisions ...
Oncocyte Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 17, 2021 16:01 ET
|
Oncocyte Corporation
-Oncocyte Q1 revenues beat consensus estimate, driven by strong DetermaRx and Pharma Services growth - -Data in four indications (TNBC, NSCLC, bladder, and renal cell cancer) suggest pan-cancer...
Medicare Coverage Determination for Molecular Testing Announced for Solid Organ Allograft Rejection, Citing Multiple Publications from OncoCyte Corporation’s Subsidiary Chronix Biomedical, Inc.
May 06, 2021 08:00 ET
|
Oncocyte Corporation
Coverage policy for transplant rejection monitoring establishes a simplified and accelerated pathway for Medicare coverage of Chronix’s solid organ transplant rejection monitoring test Oncocyte’s...
Oncocyte to Report First Quarter 2021 Financial Results on Monday, May 17
May 04, 2021 16:01 ET
|
Oncocyte Corporation
IRVINE, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across...
Oncocyte to Present New Data on DetermaIO™ Test as a Predictor of Immunotherapy Response in Renal Cell Cancer at the 2021 ASCO Annual Meeting
April 28, 2021 16:31 ET
|
Oncocyte Corporation
IRVINE, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across...
Oncocyte Enters the Rapidly Growing Immune Therapy Monitoring Market with the Closing of the Acquisition of Chronix Biomedical, Inc.
April 19, 2021 08:00 ET
|
Oncocyte Corporation
Oncocyte gains proprietary capabilities for immune therapy monitoring and transplant rejection testing, both from a standard blood sample Oncocyte’s technologies may provide more precision to the...
Oncocyte Hosting Key Opinion Leader Call on Novel Biomarkers in Identifying Appropriate Responders to Immune Checkpoint Inhibitors
April 14, 2021 09:02 ET
|
Oncocyte Corporation
IRVINE, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across...